# Subsense

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/subsense

- Industry: Biotechnology
- Headquarters: Covina, US
- Website: www.subsense-bci.com
- Total disclosed funding: $25M
- Latest round: Seed (Dec 11, 2025)
- Investors on record: 1

## About

Subsense Inc. focuses on developing non-surgical bidirectional brain-computer interfaces (BCIs) that enhance human capabilities and improve health, primarily targeting individuals with paralysis and neurological disorders.Founded in 2022 in Covina, US, Subsense Inc. specializes in non-surgical brain-computer interface technology. Founded in 2022 in Covina, US, Subsense Inc. specializes in non-surgical brain-computer interface technology. The company has executed 2 deal, with its most recent funding round occurring on December 11, 2025. Founder details are not available, and no mention of subsidiaries or prior mergers exists. The company raised USD 10.00 mn in a Seed round from Golden Falcon Aviation, marking the total amount raised to USD 27.00 mn. Subsense specializes in the development of non-surgical bidirectional brain-computer interfaces (BCIs) designed to transform health and enhance human capabilities. The core product leverages biocompatible nanoparticles engineered to stimulate and record neural activity, facilitating seamless communication between human cognition and technology. The BCI technology primarily targets individuals with paralysis and neurological disorders, enabling them to control digital devices through thought alone, thereby improving independence and quality of life. Applications extend to treating neurological and neurodegenerative diseases, providing real-time diagnostics, and enhancing human-machine interaction across various platforms. Subsense aims to introduce its innovative solutions to markets in North America and Europe, with an emphasis on accessibility and safety for end-users.Subsense's revenue model is structured around B2B partnerships and direct-to-consumer engagements, focusing on healthcare providers and technology integrators. The company offers its flagship BCI technology through customized solutions tailored to specific client needs, which may include subscription-based services for ongoing support and upgrades. Revenue streams are generated through initial product sales and recurring fees associated with software updates and maintenance. Clients include healthcare facilities and research institutions seeking advanced solutions for patient treatment and monitoring. The commercial strategy emphasizes long-term collaborations, ensuring alignment with market demands and enhanced product offerings. The company will use the December 2025 funding to advance research and development of its non-surgical brain-computer interface, focusing on nanoparticle sensing, safety testing, improved device design, and smaller hardware components. Plans for the future include the development of additional BCI products targeting new therapeutic applications, with a focus on launching these new offerings within the next 18 months. Subsense is also planning to expand its market presence into Europe by 2026, aiming to establish critical partnerships with healthcare providers.

## Funding rounds

- Seed, Dec 11, 2025, $9.4M — Golden Falcon Capital
- Seed, Feb 18, 2025, $16M — Golden Falcon Capital

## Investors

- Golden Falcon Capital (https://capitalatlas.ai/funds/golden-falcon-capital) — Seed